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E-mail address: mtbedford@mdanderson.org (M.TArginine methylation is a common posttranslational modiﬁcation (PTM). This type of PTM occurs on
both nuclear and cytoplasmic proteins, and is particularly abundant on shuttling proteins. In this
review, we will focus on one aspect of this PTM: the diverse roles that arginine methylation of
the core histone tails play in regulating chromatin function. A family of nine protein arginine meth-
yltransferases (PRMTs) catalyze methylation reactions, and a subset target histones. Importantly,
arginine methylation of histone tails can promote or prevent the docking of key transcriptional
effector molecules, thus playing a central role in the orchestration of the histone code.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Arginine methylation
The mammalian family of protein arginine methyltransferases
(PRMTs) has nine members. These enzymes transfer a methyl
group from S-adenosylmethionine (AdoMet) to a guanidino nitro-
gen of arginine resulting in S-adenosylhomocysteine (AdoHcy)
and methylarginine. The PRMT family of AdoMet-dependent meth-
yltransferases harbor a set of four conserved signature amino acid
sequence motifs (I, post-I, II, and III), and a THW loop [1]. Motifs I,
post-I, and the THW loop form part of the AdoMet-binding pocket
[2]. There are three main forms of methylated arginine identiﬁed in
mammalian cells: monomethylarginines (MMA); asymmetric
dimethylarginines (ADMA); and symmetric dimethylarginines
(SDMA). PRMTs are classiﬁed as either type I, type II, or type III,
enzymes, which methylate the terminal (or x) guanidino nitrogen
atoms of arginine. Type IV enzyme activity catalyzes the monom-
ethylation of the internal guanidine nitrogen atom and this type
of activity has only been described in yeast. Type I and type II
enzymes catalyze the formation of an MMA intermediate, then
type I PRMTs (PRMT1, 2, 3, 4, 6, and 8) further catalyze the
production of ADMA, while type II PRMTs (PRMT5 and 7) catalyze
the formation of SDMA (Fig. 1A). Certain substrates are only
monomethylated by PRMT7, which is referred to as type III
enzymatic activity. Histone tails are a prime target for this family
of enzymes (Fig. 1B).chemical Societies. Published by E
. Bedford).2. Mammalian arginine methyltransferases
2.1. Prmt1
PRMT1 was the ﬁrst mammalian protein arginine methyltrans-
ferase identiﬁed [3], and it is also responsible for the bulk (about
85%) of total protein arginine methylation activity [4]. The central
role that PRMT1 plays as a diverse regulator of protein function is
revealed by the disruption of this enzyme in mice, which die
shortly after implantation [5]. PRMT1 displays wide substrate
speciﬁcity, with a preference for methylating arginine residues that
are ﬂanked by one or more glycine residues – motifs often referred
to as GAR sequences (Glycine and Arginine Rich) [6,7]. The three-
dimensional structure of PRMT1 reveals that it is active as a
homodimer [8]. PRMT1 also methylates histone H4 at arginine 3,
generating the H4R3me2a mark [9], and thus contributing to the
histone code. This modiﬁcation on histone H4 functions as a tran-
scriptional activation mark, which can recruit methyl-binding pro-
teins and inﬂuence the deposition of other posttranslational marks
in the vicinity. As a transcriptional coactivator, PRMT1 is recruited
to promoters by a number of different transcription factors [10].
2.2. Prmt2
PRMT2 harbors a methyltransferase domain and a SH3 domain
[11]. The SH3 domain binds the PRMT8 N-terminal domain and
may also target it to substrates [12]. Initially, it was not believed
to possess methyltransferase activity. However, recently very weak
Type I activity was eked out of this enzyme [13]. PRMT2 canlsevier B.V. All rights reserved.
Fig. 1. Types and sites of histone tail arginine methylation. (A) Arginine residues in the tails of histones can be monomethylarginines (MMA), asymmetric dimethylarginines
(ADMA), and symmetric dimethylarginines (SDMA). The MMA form of arginine is generally regarded as an intermediate on its way to the dimethylated state and is not
depicted here. (B) The known sites of histone H3, H4, and H2A arginine dimethylation are shown. Red denotes transcriptional repressor activity and green denotes
transcriptional activator activity.
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been mapped. PRMT2 is a coactivator of gene expression much like
PRMT1 and CARM1, and this activity appears to rely upon the
integrity of the methyltransferase domain. PRMT2 is a coactivator
of both the androgen receptor and the estrogen receptor alpha
[14,15]. In addition, PRMT2 can promote apoptosis and inhibit
NF-kappaB function by blocking IkappaB-alpha nuclear export
[16]. PRMT2 null mice are viable and grossly normal [17].
2.3. Prmt3
PRMT3 harbors a zinc-ﬁnger domain at its N-terminus, which is
the substrate recognition module of this enzyme [18,19]. The 40S
ribosomal protein S2 (rpS2) is a zinc-ﬁnger dependent substrate
of mammalian PRMT3 [20]. Importantly, in ﬁssion yeast PRMT3
(called Rmt3) also methylates rpS2 [21], emphasizing the con-
served nature of this enzyme/substrate pairing. In yeast, loss of
PRMT3 results in a ribosomal subunit imbalance, which can be re-
stored with the expression of a catalytic inactive mutant [22].
Mouse embryos with a targeted disruption of PRMT3 are small in
size, but survive after birth and attain a normal size in adulthood.
In these null mice, rpS2 is hypomethylated, demonstrating that it is
an in vivo PRMT3 substrate [23]. PRMT3 seems to be located exclu-
sively in the cytosol, thus it may not directly impact epigenetic
pathways.
2.4. Carm1 (prmt4)
CARM1, which is also referred to as PRMT4, was identiﬁed as a
steroid receptor coactivator and provided the ﬁrst evidence that
arginine methylation regulates transcription [24]. The recruitment
of CARM1 to transcriptional promoters results in the methylation
of histone H3 (H3R17me2a and H3R26me2a) and transcriptional
regulators [10]. CARM1 is not only a steroid receptor coactivator,
but it also reinforces other transcription factor pathways [10]. In
addition, CARM1methylates splicing factors and regulates the cou-
pling of transcription and splicing [25]. CARM1 and PRMT1 do notshare substrates [7]. CARM1 null mice die just after birth and are
smaller than their wild-type littermates [26]. Further analysis of
these null mice have revealed key in vivo roles for CARM1 in early
T cell development [27], in adipocyte differentiation [28], in chon-
drocyte proliferation [29], and in the proliferation and differentia-
tion of pulmonary epithelial cells [30]. CARM1 requires its
enzymatic activity for all of its known in vivo functions [31].
2.5. Prmt5
PRMT5 is the predominant Type II arginine methyltransferase in
mammals and is generally regarded as a strong transcriptional
repressor [32]. It was ﬁrst identiﬁed as a Jak2-binding protein
and shown to methylate histones H2A, H3, and H4 [33,34]. In the
nucleus, PRMT5 binds to COPR5 (cooperator of PRMT5), which
appears to be responsible for its transcriptional corepressor activ-
ities. The COPR5 interaction alters the speciﬁcity of PRMT5, causing
it to preferentially methylate H4R3 over H3R8 [35]. PRMT5 is
recruited by numerous transcription factors and repressor com-
plexes, including Snail [36], ZNF224 [37], Ski [38], and at the globin
locus [39]. In the cytoplasm, PRMT5 is involved in snRNP biogene-
sis through its ability to methylate a number of Sm proteins
[40,41], and it also methylates Piwi proteins, which regulate a class
of small non-coding RNAs [42]. It should be noted that aFLAG
M2-agarose enriches for PRMT5 activity [43], thus many afﬁnity
puriﬁed FLAG-tagged complexes are ‘‘contaminated’’ with PRMT5,
confounding the ﬁeld.
2.6. Prmt6
PRMT6 is predominantly localized to the nucleus and like
PRMT1 methylates GAR motifs [44]. It is the primary enzyme
responsible for H3R2 methylation in mammalian cells, [45–47].
H3R2methylation, by PRMT6, counteracts the H3K4me3 activation
mark, making it a transcriptional repressor. Thrombospondin-1
(TSP-1) is the ﬁrst characterized transcriptionally repressed target
of PRMT6 [48]. The general assumption that PRMT6 functions as a
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strates that it functions as a coactivator with nuclear receptors
[49]. The ability of PRMT6 to function as a coactivator may be
linked to its capacity to also methylate the R3 position of the N-ter-
minal tails of histones H4 and H2A (the ﬁrst 5 residues of these his-
tones are the same) [46]. Thus, in certain contexts, PRMT6 may
methylate H3R2 and repress transcription, and in other contexts,
it may methylate H4R3/H2AR3 and activate transcription – this
hypothesis needs to be conﬁrmed.
2.7. Prmt7
PRMT7 is one of two PRMTs that harbor two putative AdoMet-
binding motifs [50]. Indirect evidence correlates PRMT7 activity
with either resistance or sensitivity to DNA damaging agents
[51–53], and sensitivity of the kidney to damage caused by certain
antibiotics [54]. The in vitro enzymatic activity of PRMT7 is not
particularly robust, but it has been described as having type III
activity towards some substrates [55] and type II activity towards
others [56]. It is thus possible that distinct substrates are methyl-
ated in different fashions by this enzyme. PRMT7 plays a role in
male germline imprinted gene methylation through its interaction
with CTCFL and subsequent symmetrical methylation of H4R3 [57].
PRMT7 might also play a role in embryonic stem cell (ESC) pluripo-
tency, as its expression is lost when ESCs differentiate [58].
2.8. Prmt8
PRMT8 displays a high degree of sequence identity with PRMT1
[59]. It has a unique N-terminal end that harbors a functional
myristoylation motif that facilitates its association with the plasma
membrane. This myristoylation motif is conserved in the puffer
ﬁsh orthologue of PRMT8 (fuguL3) [60]. The alternate use of initi-
ator methionine residues may affect the localization of the endog-
enous protein [61]. Furthermore, PRMT8 expression is largely
restricted to the brain, and more speciﬁcally to neurons. The
in vitro activity of the full-length recombinant enzyme is low;
however, removal of the N-terminal domain by truncation or pro-
teolysis results in increased activity [12]. The N-terminal region
contains two proline-rich sequences that can bind a number of
SH3 domains, including that of PRMT2.
2.9. PRMT9 (4q31)
PRMT9 (4q31) was ﬁrst identiﬁed at the same time as PRMT8
was described [59]. PRMT9, like PRMT7, harbors two putative Ado-
Met-binding motifs. In addition, at its N-terminal end, PRMT9 has
two tetratricopeptide repeats (TPR), which often mediate protein–
protein interactions [62]. We refer to this protein with the human
chromosomal location, because the PRMT9 designation has also
been used for the product of the human FBXO11 gene on chromo-
some 2p16 [63], although FBXO11 is unlikely to be a bona ﬁde PRMT
[64]. PRMT9 (4q31) has yet to be biochemically characterized.3. Arginine demethylation
Arginine methylation is a very stable mark, and it is unclear if
the modiﬁcation can be enzymatically reversed. This is a very ac-
tive ﬁeld of investigation.
3.1. Jmjd6
The ﬁrst putative arginine demethylase was recently identiﬁed
[65]. This enzyme, JMJD6, a Jumonji domain-containing protein,
was reported to demethylate H3R2me2 and H4R3me2. Further-more, it could demethylate both, asymmetrically and symmetri-
cally, dimethylated substrates. Recently, these ﬁndings were
brought into question by studies performed by Webby et al., who
showed that JMJD6 is actually a lysine-hydroxylase [66]. They were
unable to detect demethylase activity on either H3R2me2 or
H4R3me2 peptides. In addition, the structural analysis of JMJD6
suggests that it is not an arginine demethylase [67,68]. Thus, the
issue of whether an arginine demethylase really exists remains
unanswered.
3.2. PADIs
Arginine residues are not only substrates for methylation, they
can also be converted to citrulline by deimination [69]. The conver-
sion of arginine to citrulline is catalyzed by a family of enzymes
called peptidylarginine deiminases (PADIs). The core histones
H2A, H3, and H4 comprise a major group of deiminated proteins
[70]. PADI4 is a nuclear protein that targets the same arginine res-
idues on histones H3 and H4 as the PRMTs methylate [71,72]. A re-
cent study showed that PADI4 is recruited to the pS2 promoter
region just prior to H3R17me2a loss, suggesting that it is responsi-
ble for removing this methyl-mark [73]. However, PADIs catalyze
the deimination of arginine, but not methylated arginine residues
[74,75]. Furthermore, no enzyme has been identiﬁed than can con-
vert citrulline back to arginine. Thus, PADIs can block methylation
on an arginine residue by converting it to citrulline, but are not
‘‘true’’ demethylases.4. Sites of arginine methylation on histone tails
Methyl-speciﬁc antibodies have been raised to many of the
arginine methylation sites on histone tails. These antibodies have
been used in a variety of studies, including traditional ChIP, ChIP-
chip, and ChIP-seq experiments. Here we will summarize these
ﬁndings, and attempt to consolidate them into uniﬁed rules that
will associate a speciﬁc mark with a speciﬁc chromatin state. In
some cases, these attempts fall short because of conﬂicting data
in the literature.
4.1. H3R17me2a
The H3R17me2a mark is generated by CARM1 [76], which was
the ﬁrst PRMT to be identiﬁed as a transcriptional regulator [24].
CARM1 has been deﬁnitively characterized as a coactivator, and
it functions as such with nuclear receptors and a variety of addi-
tional transcription factors including p53, NF-jB, PPARc, and
c-Fos [77]. Indeed, ChIP analysis has identiﬁed elevated levels of
H3R17me2a at the promoters of pS2 [78,79], E2F1 [80], CCNE1
[81], aP2 [28], Oct 4 and Sox2 [82], CITED2 [83], and Scn3b [30].
It should be noted here that the H3R17me2a antibody [UpState],
used for the vast majority of these ChIP experiments, recognizes
a number of different CARM1 substrates, including AIB1 and a
cohort of splicing factors [25,26,84]. Thus, this antibody is a great
reporter for CARM1 activity, but not a speciﬁc readout for
H3R17me2a methylation per se.
Kinetic ChIP analysis of the estrogen-responsive pS2 promoter
reveals that CARM1 is recruited in a cyclic manner, occurring at
40 min intervals after E2-treatment [85]. This recruitment of
CARM1 correlates with an increase in the H3R17me2 mark, which
arises at the same time that CBP/p300 is recruited. The concomi-
tant recruitment of CARM1 with CBP/p300 is important for
H3R17me2 methylation, because acetylation of H3K18 makes the
histone H3 tail a better substrate for CARM1 [86]. Crosstalk
between CARM1 and p300 also occurs at the GADD45 gene, which
is regulated by p53 [87]. A detailed analysis of this H3K18ac
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does not enhance its afﬁnity for CARM1, but instead this priming
increases the rate of the methyltransferase reaction itself [88]. It
is proposed that by neutralizing the positive charge, acetylation
of H3K18 would facilitate the nucleophilic attack on the sulphur–
methyl bond of SAM, thus explaining why CARM1 has ﬁvefold
higher activity towards the H3K18ac-peptide than the unmodiﬁed
peptide. Furthermore, the methylation of the H3R17 mark may be
regulated in a cell cycle-dependent manner. Histones isolated from
M-phase cells harbor the highest level of H3R17 methylation, and
this peak in signal correlates well with the H3S10p [89].
Recently, the ﬁrst genome wide localization of CARM1 activity
(the H3R17me2a mark) was performed using a ChIP-chip approach
[90]. In MCF7 breast cancer cells, CARM1 activity was localized to
distinct classes of ERa binding sites that have been termed enhan-
cer-rich clusters Ec1 and Ec3. Surprisingly, CARM1 activity local-
izes to enhancer regions that are a great distance away from the
transcription start sites (TSS) of the genes that undergo E2-stimu-
lated gene expression. Thus CARM1 activity maps to ERa-speciﬁc
enhancers rather than promoter regions, although a number of
groups have ChIPed CARM1 activity at the estrogen-responsive
pS2 promoter [78,79,85]. The pS2 promoter may represent an
exception, because ERa is recruited to both its promoter and en-
hancer regions [91]. ChIP-seq experiments for CARM1 or CARM1
activity have not yet been reported.
4.2. H3R26me2a
The H3R26me2a mark is also generated by CARM1 [76],
although this modiﬁcation has not been studied much. This mark
has been identiﬁed at the CCNE1 promoter using a ChIP approach
[81]. An interesting feature of the H3R26 site is its proximity to
H3K27, which when methylated is a major repressive mark. If the
H3R26me2a mark antagonizes the Polycomb repressive function
(by either preventing EZH2 methylation of H3K27, or blocking the
docking of the Polycomb family of chromodomains and/or the
EED WD40 domain to H3K27me3 [92,93]), then profound effects
on gene expression would be expected. These studies have yet to
be performed.
4.3. H3R2me2a
The H3R2me2a mark was initially thought to be generated by
CARM1 [76], but recent studies have identiﬁed it as a major mark
deposited by PRMT6 [45–47]. Methylation of the H3R2 site essen-
tially prevents the MLL1 complex from methylating H3K4 [46].
However, PRMT6 can strongly methylate H3K4me1 and H3K4me2
peptides, and weakly methylate a H3K4me3 peptide, so dually
modiﬁed histone tails likely exist [47]. H3K4me3 marks the TSS of
actively transcribed genes. Many effectors that bind H3K4me3 are
blocked from docking if H3R2 is also methylated [47]. Thus, PRMT6
functions as a transcriptional repressor by blocking the recruitment
of transcriptional activators to the methylated H3K4 mark. ChIP
analysis at 185 human promoters supports this hypothesis, demon-
strating a counter-correlation between H3K4me3 and H3R2me2a
levels [45]. This study also shows a counter-correlation between
H3R2me2a and gene expression levels. Further ChIP analysis has re-
vealed PRMT6 activity at the promoters of the HoxA2 gene [46] and
the TSP-1 gene [48],which correlatewith transcriptional repression.
The ﬁrst ChIP-seq survey to be performed on histone methyl-
arginine marks found no enrichment of H3R2me1 or H3R2me2a
at either active or silenced gene promoters [94]. However, more
recent ChIP-seq studies have revealed enrichment of the
H3R2me2a mark at pericentromeric regions, and H3R2me1 mark
at subtelomeric regions [95]. This same study also shows that both
the H3R2me1 and H3R2me2a marks are associated with highlyexpressed genes, which is rather unexpected considering the ChIP
experiment described above and the ability of the H3R2me2a mark
to block H3K4me3 effector molecules. However, this report is con-
sistent with the ﬁnding that PRMT6 functions as a coactivator of a
number of nuclear receptors [49]. Of course, the capacity of PRMT6
to function as a coactivator may be due to its ability to also meth-
ylate H4R3me2a, which is associated with active chromatin. The
interaction of PRMT6 with different regulators may alter its sub-
strate speciﬁcity (H3R2me2a or H4R3me2a), thus allowing this
PRMT to toggle between an activator and a repressor.
4.4. H4R3me2a and H2AR3me2a
The ﬁrst ﬁve residues of histones H4 and H2A are identical, and
it is thus likely that most of the activities reported for H4R3 will
also hold true for H2AR3. Importantly, antibodies raised against
H4R3 methylation marks will also recognize H2AR3. We will thus
refer to these two sites jointly as the ‘‘R3 motif’’. The fact that this
motif has been duplicated, provides an efﬁcient means of amplify-
ing the signaling that are mediated by these two histone tails.
The asymmetric dimethylation of the R3 motif is catalyzed by
PRMT1, PRMT6, and PRMT8 [9,46,47], and is associated with ac-
tively transcribed promoters. PRMT1 functions as a coactivator
with ER, YY1, p53, and RUNX1 [77]. ChIP analysis has identiﬁed
elevated levels of R3 motif methylation at the promoters of pS2
[73], CYP3A4 [96], CITED2 [83], and the b-globin locus [97].
Kinetic ChIP analysis of the estrogen-responsive pS2 promoter
reveals that PRMT1 is recruited in cyclic manner, and is the ﬁrst
PRMT to be recruited after an E2 pulse [85]. PRMT1 recruitment
and its subsequent methylation of the R3 motif occurs during the
ﬁrst transcriptionally non-productive cycle, and deﬁnes the tran-
scriptional competency of the pS2 promoter. This is consistent
with the fact that R3 motif methylation is required for the subse-
quent acetylation of histone H3 and H4 [97,98]. Interestingly,
while the H3R17me2a marks every transcriptionally productive
cycle (at 40 min intervals), methylation of the R3 motif covers
two of these cycles before it is lost and then re-established again.
This phenomenon has been observed in at least two independent
studies [73,85] and remains unexplained.
Using a Top Down mass spectrometric approach, the possible
combinations of different histone H4 modiﬁcations were quanti-
ﬁed [99]. Less than 2% of total histone H4 is mono- or di-methyl-
ated at the H4R3 site. This study did not distinguish between
symmetric and asymmetric dimethylation at H4R3. However, they
did report that the H4R3me species is often also lysine acetylated,
which is consistent with transcriptional activation. A second mass
spectrometric study also found H4R3 methylation in combination
with extensive acetylation, and always with the H4K20me2 mark
[100].
4.5. H4R3me2s and H2AR3me2s
PRMT5 symmetrically methylates both H3R8 and the R3 motif
[101], but its speciﬁcity is tilted towards the R3 motif by one of
its regulatory binding proteins, COPR5 [35]. There is evidence that
PRMT7 can also methylate these sites [57]. H4R3me2s motif ChIP
experiments for PRMT5 target genes have been performed, localiz-
ing this mark to repressed promoter regions [102], and the silenced
fetal globin gene [39]. Chip experiments have also identiﬁed the
R3me2s motif mark at sites within the H19 imprinting control
region [57]. ChIP-seq experiments have been performed for
the H4R3me2s mark by Keji Zhao’s group [94]. Unexpectedly,
they did not ﬁnd any correlation between this mark and transcrip-
tionally repressed loci. However, reevaluation of this data, by a
different group, indicated that the H4R3me2s mark is strongly
associated with repressed gene expression [103].
Fig. 2. Mechanisms by which histone tail arginine methylation regulates tran-
scription. (A) The symmetrical dimethylation of H3R2 blocks the binding of
2028 A. Di Lorenzo, M.T. Bedford / FEBS Letters 585 (2011) 2024–2031As mentioned above, this R3 motif is also a site for asymmetric
methylation (an activation mark) by a number of enzymes. Thus, at
genes that are actively maintained in an ‘‘on’’ or ‘‘off’’ state there is
constant pressure on this bifunctional site to be either asymmetri-
cally or symmetrically dimethylated.
4.6. H3R8me2s
The H3R8 site is symmetrically methylated by PRMT5 [101].
This methylation event is linked to transcriptional repression and
is tightly associated with H4R3me2s methylation, which is also
generated by PRMT5. PRMT5 is recruited by numerous transcrip-
tional repressors, including Snail, ZNF224 and Ski [36–38].
H3R8me2s ChIP experiments for a number of PRMT5 target genes
have been performed, localizing this mark to repressed promoter
regions [102].
The prior acetylation of H3K9 or H3K14 prevents the methyla-
tion of H3R8 by PRMT5 [101]. The reverse has not been tested,
so it is not clear if the H3R8me2s modiﬁcation has an impact on
H3K9 acetylation. However, G9a methylation of H3K9 is blocked
by the prior existence of the H3R8me2s modiﬁcation [104]. Also,
the recognition of the guanidinium amino group of H3R8 contrib-
utes to sequence speciﬁcity of H3S10ph recognition by 14-3-3f
[105]. The effect of H3R8 methylation on H3K9me3 recognition
by chromodomain-containing proteins (HP1, MPP8 or CDYs) has
not yet been established. Thus, the mechanism by which H3R8
methylation links to transcriptional repression remains unclear,
but a number of intriguing possibilities exist. Genome-wide chro-
matin proﬁles of PRMT5 or H3R8me2s have not yet been reported.H3K4me3 effector molecules. In addition, the H3R2me2a mark prevents methyl-
ation of H3K4me3 by MLL1. (B) The H4R3me2s mark may function as a docking site
for the PHD ﬁnger of the de novo DNA methyltransferase DNMT3A, thereby linking
PRMT5 activity to stable and heritable DNA methylation. (C) The activation marks
deposed by PRMT1 (H4R3me2a) and CARM1 (H3R17me2a) can be ‘‘read’’ by the
tudor domain of TDRD3. TDRD3 itself functions as a coactivator, in some manner
relaying the intent of these two PRMTs.5. The consequences of histone tail arginine methylation
The different arginine methylation events that occur on histone
tails likely impact the generation of other histone code marks and/
or inﬂuence the binding of effector molecules. Here we will high-
light a few examples of these different means of regulation.
5.1. Blocking the docking of effector molecules
It is clear that there is cross-talk between lysinemethylation and
serine phosphorylation on histone tails [106]. In a similar fashion, it
has been proposed that cross-talk between arginine and lysine
methylation is also a wide-spread phenomenon, and has been
termed an ‘‘arginine/lysine-methyl/methyl switch’’ [107]. A num-
ber of arginine/lysine pairs exist, i.e. H3R2/H3K4; H3R8/H3K9;
H3R26/H3K27, where both residues are methylated. Furthermore,
there are many more of these potential switches on the histone
tails.
One of these sites of cross-talk that has been well-deﬁned is the
H3R2/H3K4 switch (Fig. 2A). PRMT6 is the primary enzyme
responsible for the methylation of H3R2 in mammalian cells
[45–47]. In mammalian cells, these two marks may coexist,
because PRMT6 can strongly methylate H3K4me1 and H3K4me2
peptides, and weakly methylate a H3K4me3 peptide [47]. How-
ever, prior methylation of the H3R2 site essentially prevents the
MLL1 complex from methylating H3K4 [46]. It is not clear whether
other H3K4 methyltransferases (there are at least nine of them) are
active on a H3R2me2a substrate. Methylation of H3K4 is found at
the 50 end of active genes and is responsible for recruiting
chromatin-remodeling enzymes to establish and maintain a trans-
criptionally active state. The effectors that bind H3K4me3 harbor
methyl-speciﬁc binding domains, including PHD, Chromo, Tudor,
andWD40 domains. Methylation at the H3R2 site blocks the ability
of most of these domains to bind the N-terminal tail of histone H3,
in in vitro assays [47]. In cells, the chromatin binding of bothWDR5 and ING2 is sensitive to the level of PRMT6 expression
[45–47]. Thus, PRMT6 functions as a transcriptional repressor by
blocking the recruitment of transcriptional activators to the meth-
ylated H3K4 mark.
5.2. Recruitment of repressive effector molecules
Do readers of symmetrically methylated arginine motif exist? If
there are SDMA binders, these effector molecules should possess
repressor functions that would link PRMT5 (and PRMT7) to its
clearly deﬁned role as an attenuator of transcription. Recently,
the PHD domain of the de novo DNA methyltransferase DNMT3A
was identiﬁed as a binder of the H4R3me2s mark [108]. A repres-
sive mechanism can now be envisioned where PRMT5 is recruited
to a promoter, generating a patch of H4R3me2s that in turn will
facilitate the binding of DNMT3A, thereby promote DNA methyla-
tion and prolonged gene silencing (Fig. 2B). This sequence of events
has been challenged by Otani et al., who conﬁrmed previous re-
ports that the PHD domain (also called the ADD domain) of
DNMT3A binds H3K4me0 [109], but were not able to reproduce
the interaction between this PHD and a H4R3me2s peptide [110].
5.3. Recruitment of effector molecules with activator functions
Do readers of asymmetrically methylated arginine motif exist?
If there are ADMA binders, these effector molecules should possess
activator functions that would link PRMT1 and CARM1 to their
clearly deﬁned roles as transcriptional coactivators. Using a protein
domain microarray approach, one such effector molecule was
recently identiﬁed [111]. TDRD3 contains a tudor domain that
A. Di Lorenzo, M.T. Bedford / FEBS Letters 585 (2011) 2024–2031 2029binds both the H3R17me2a and H3R4me2a activator marks
(Fig. 2C). TDRD3 itself functions as a coactivator in ERE-luciferase
assays. Furthermore, endogenous TDRD3 ChIPs at the pS2 pro-
moter in a estrogen-dependent manner, and global ChIP-seq anal-
ysis reveals that TDRD3 is highly enriched at the promoters of
actively transcribed genes. Although TDRD3 is recruited to estro-
gen-responsive promoters in an estrogen-dependent manner, it re-
mains unclear how it promotes transcriptional activation. Indeed,
TDRD3 harbors no enzymatic activity. It is thus likely that TDRD3
recruits a protein complex that assists in opening and activating
chromatin in the vicinity of H3R17me2a and H4R3me2a activator
marks.
6. Exciting prospects for the near future
It is likely that we have identiﬁed all the arginine methyltrans-
ferases within this particular PRMT family. It is possible that con-
vergent evolution has generated other classes of arginine
methyltransferases, as it has for lysine methyltransferases and
demethylases. The search and identiﬁcation of additional effector
molecules that ‘‘read’’ ADMA and SDMA motifs will be critical to
help us understand the mechanisms of action of this posttransla-
tional modiﬁcation. Clearly, a comprehensive ChIP-seq analysis of
all the arginine methylated histone code marks is required for us
to better understand the roles of each mark. New arginine methyl-
ation sites will likely be identiﬁed on histone tails in the coming
years. The novel marks may well exist in the context of ‘‘argi-
nine/lysine-methyl/methyl switch’’. These ‘‘switches’’ have not at-
tracted much attention, and the importance of the H3R8/H3K9 and
H3R26/H3K27 nodes have yet to be determined. The holy grail in
the ﬁeld remains the elusive arginine demethylases.
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